La chaîne d'options affiche les données clés des options sur actions de DTE Energy Company 2020 Series G 4.375% Junior Subordinated Debentures due 2080 à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour DTE Energy Company 2020 Series G 4.375% Junior Subordinated Debentures due 2080..

DTE Energy Company 2020 Series G 4.375% Junior Subordinated Debentures due 2080 (NYSE:DTB) Stock, Chaîne d'Options

DTE Energy Company 2020 Series G 4.375% Junior Subordinated Debentures due 2080

Tractor Supply (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSCO#NASDAQ">TSCO</a>) is looking for Q2 GAAP EPS of $0.79-$0.81 vs $0.84 analyst estimate. sees sales of $4.374 billion-$4.417 billion vs $4.47 billion analyst estimate.

News

Guidance

TSCO

Tractor Supply Sees Q2 GAAP EPS $0.79-$0.81 vs $0.84 Est; Sees Sales $4.374B-$4.417B vs $4.47B Est

Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) lowers FY2025 GAAP EPS guidance from $6.62-$6.74 to $6.38-$6.50 vs $6.66 analyst estimate..

Procter & Gamble Lowers FY2025 GAAP EPS Guidance from $6.62-$6.74 to $6.38-$6.50 vs $6.66 Est

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates MAG Silver (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MAG#AMEX">MAG</a>) with a Buy and maintains $22 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on MAG Silver, Maintains $22 Price Target

Rosenblatt analyst Steve Frankel maintains Imax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IMAX#NYSE">IMAX</a>) with a Buy and maintains $35 price target.

IMAX

Rosenblatt Maintains Buy on Imax, Maintains $35 Price Target

Extensive pan-cancer validation data from over 3,000 plasma samples to be presented at ASCO
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com%2F&amp;esheet=54243019&amp;newsitemid=20250424920561&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=1&amp;md5=9c36e2d7b0648c477e4e23a940d6b1d2">Natera, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), a global leader in cell-free DNA and genetic testing, today announced that its ultra-sensitive Signatera Genome assay is now broadly available to physicians in the United States.
This launch is supported by a large genome-based molecular residual disease (MRD) study, which was accepted and will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. In this clinical validation study of more than 3,000 samples from multiple cancer types – including breast cancer, colorectal cancer, non-small cell lung cancer, melanoma, and renal cell carcinoma – Signatera Genome was able to detect circulating tumor DNA (ctDNA) significantly ahead of clinical recurrence with excellent performance. In addition, postsurgical Signatera-positive patients had inferior recurrence-free survival compared to Signatera-negative patients, consistently across the different cancers that were evaluated. Additional clinical utility data on the Signatera Genome assay, including predictive data, will be presented at the conference.
Signatera Genome is available in CLIA, IUO and RUO and was designed to improve patient management as an ultra-sensitive assay for the detection of ctDNA. The test's bespoke assay is designed from a whole genome sequence of a patient's tumor and matched normal DNA. It benefits from Natera's <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.natera.com%2Fcompany%2Fnews%2Fnatera-expands-intellectual-property-portfolio-with-new-patents-in-tumor-informed-mrd%2F&amp;esheet=54243019&amp;newsitemid=20250424920561&amp;lan=en-US&amp;anchor=patented&amp;index=2&amp;md5=9185737f23159d28b6c15068250d6793">patented</a> multiplex polymerase chain reaction and next generation sequencing technology (mPCR-NGS), using a targeted and deep sequencing approach to detect tiny traces of tumor DNA at frequencies as low as 1 part per million (PPM). An RUO version of the assay is available that detects below 1 PPM.
"We are extremely pleased with the emerging evidence for our Signatera Genome assay, providing an ultrasensitive MRD detection tool for physicians," said Alexey Aleshin, M.D., general manager of oncology and corporate chief medical officer. "We look forward to sharing the results of this study, which further demonstrates the clinical utility of Signatera across disease indications."

Biotech

General

NTRA

Natera Announces That Its Ultra-Sensitive Signatera Genome Assay Is Now Broadly Available To Physicians In The United States.

Ameriprise Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMP#NYSE">AMP</a>) reported quarterly earnings of $9.50 per share which beat the analyst consensus estimate of $9.11 by 4.28 percent. This is a 13.23 percent increase over earnings of $8.39 per share from the same period last year. The company reported quarterly sales of $4.35 billion which missed the analyst consensus estimate of $4.40 billion by 1.03 percent. This is a 5.02 percent increase over sales of $4.15 billion the same period last year.

Earnings

Earnings Beats

Earnings Misses

Ameriprise Finl Q1 Adj. EPS $9.50 Beats $9.11 Estimate, Sales $4.35B Miss $4.40B Estimate

Interpublic Gr of Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IPG#NYSE">IPG</a>) reported quarterly earnings of $0.33 per share which beat the analyst consensus estimate of $0.27 by 22.22 percent. This is a 8.33 percent decrease over earnings of $0.36 per share from the same period last year. The company reported quarterly sales of $2.32 billion which beat the analyst consensus estimate of $1.98 billion by 17.24 percent. This is a 6.97 percent decrease over sales of $2.50 billion the same period last year.

Interpublic Q1 Adj. EPS $0.33 Beats $0.27 Estimate, Sales $2.32B Beat $1.98B Estimate

Valley Ntl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLY#NASDAQ">VLY</a>) reported quarterly earnings of $0.18 per share which missed the analyst consensus estimate of $0.19 by 5.26 percent. This is a 5.26 percent decrease over earnings of $0.19 per share from the same period last year. The company reported quarterly sales of $478.40 million which missed the analyst consensus estimate of $483.92 million by 1.14 percent. This is a 5.15 percent increase over sales of $454.96 million the same period last year.

Valley Ntl Q1 Adj. EPS $0.18 Misses $0.19 Estimate, Sales $478.40M Miss $483.92M Estimate

CMCSA

Comcast CEO Brian L. Roberts Says "We could not be more excited for the grand opening of Epic Universe in Orlando next month and our plans to bring a new world-class theme park to the UK."

MBLY

Mobileye Global Affirms FY2025 Sales Guidance of $1.69B-$1.81B vs $1.76B Est

NovoCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.46) by 32.61 percent. This is a 13.89 percent increase over losses of $(0.36) per share from the same period last year. The company reported quarterly sales of $154.99 million which beat the analyst consensus estimate of $146.60 million by 5.72 percent. This is a 11.91 percent increase over sales of $138.50 million the same period last year.

NVCR

NovoCure Q1 EPS $(0.31) Beats $(0.46) Estimate, Sales $154.99M Beat $146.60M Estimate

First BanCorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBP#NYSE">FBP</a>) reported quarterly earnings of $0.47 per share which beat the analyst consensus estimate of $0.43 by 9.3 percent. This is a 6.82 percent increase over earnings of $0.44 per share from the same period last year. The company reported quarterly sales of $212.40 million which missed the analyst consensus estimate of $223.47 million by 4.95 percent. This is a 8.08 percent increase over sales of $196.52 million the same period last year.

First BanCorp Q1 Adj. EPS $0.47 Beats $0.43 Estimate, Sales $212.40M Miss $223.47M Estimate

Rosenblatt analyst Kevin Garrigan maintains Texas Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) with a Buy and maintains $216 price target.

Rosenblatt Maintains Buy on Texas Instruments, Maintains $216 Price Target

Old Republic Intl Q1 2025 Adj. EPS $0.81 Beats $0.74 Estimate, Sales $2.06B Beat $2.03B Estimate

Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) raises FY2025 Adj EPS guidance from $6.55-$6.85 to $6.70-$7.00 vs $6.74 analyst estimate. Raises FY2025 sales outlook from $45.50 billion to $45.80 billion-$46.80 billion vs $45.76 billion estimate.

Bristol-Myers Squibb Raises FY2025 Adj EPS Guidance from $6.55-$6.85 to $6.70-$7.00 vs $6.74 Est; Raises FY2025 Sales Guidance from $45.50B to $45.80B-$46.80B vs $45.76B Est

Mobileye Global Q1 Adj. EPS $0.08, Inline, Sales $438M Beat $435.20M Estimate

Balchem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCPC#NASDAQ">BCPC</a>) reported quarterly earnings of $1.22 per share which met the analyst consensus estimate. This is a 18.45 percent increase over earnings of $1.03 per share from the same period last year. The company reported quarterly sales of $250.52 million which beat the analyst consensus estimate of $245.70 million by 1.96 percent. This is a 4.53 percent increase over sales of $239.66 million the same period last year.

BCPC

Balchem Q1 Adj. EPS $1.22, Inline, Sales $250.52M Beat $245.70M Estimate

Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) reported quarterly earnings of $1.54 per share which beat the analyst consensus estimate of $1.53 by 0.65 percent. This is a 1.32 percent increase over earnings of $1.52 per share from the same period last year. The company reported quarterly sales of $19.78 billion which missed the analyst consensus estimate of $20.11 billion by 1.64 percent. This is a 2.07 percent decrease over sales of $20.20 billion the same period last year.

Procter & Gamble Q3 Adj. EPS $1.54 Beats $1.53 Estimate, Sales $19.78B Miss $20.11B Estimate

Minnesota Gov. Tim Walz, in his State of the State address on Wednesday, condemned President Donald Trump, accusing him of exerting the power of the federal government for personal gain and undermining fruitful leadership.
What Happened: Walz criticized Trump's <a href="https://www.benzinga.com/25/04/44969805/trump-softens-stance-on-tariffs-stock-futures-rise-nikkei-opens-higher-dollar-under-pressure">management of tariffs </a>and the controversial Department of Government Efficiency (DOGE). He called Trump's actions "small, weak, and petty," adding, "It takes the awesome power of the federal government and turns it into a crude weapon, wielded by a man who wants to be a king."
Walz has previously <a href="https://www.benzinga.com/25/03/44549724/elon-musk-blasts-minnesota-governor-tim-walz-as-a-creep-over-tesla-stock-mockery-says-its-evil-to-celebrate-others-losses">clashed</a> with Elon Musk, a close aide of Trump, over the decline of Tesla Inc.&#8217;s stock prices.
See Also: <a href="https://www.benzinga.com/news/events/25/04/44971154/trump-fails-to-impress-americas-young-shows-poll-as-they-still-favor-biden-only-15-think-us-on-right-track">Trump Says Tariffs Could Replace Income Tax: Experts Warn The Math Doesn&#8217;t Work</a>
Why It Matters: The speech was Walz's first State of the State since his defeat as part of the Democratic presidential ticket last year. It comes as he tours Republican-held districts across the country, using town halls to <a href="https://www.benzinga.com/news/25/04/44780734/tim-walz-says-its-okay-to-be-successful-but-dont-be-a-greedy-bastard-and-not-pay-your-taxes">promote </a>his critical views of the Trump administration.
In response to Walz, Republican leaders pushed back, accusing him of diverting attention to Washington instead of concentrating on the urgent work still to be done in Saint Paul.
&#8220;It was really unfortunate that while there was maybe not quite an olive branch, but maybe, a few buds of an olive tree given by the governor, most of it was overshadowed by a quite frankly angry rant about Donald Trump,&#8221; said Rep. Harry Niska, R-Ramsey, <a href="https://www.cbsnews.com/minnesota/news/minnesota-gov-tim-walz-2025-state-of-the-state/">to</a> CBS News.
Meanwhile, 
U.S. stock futures <a href="https://www.benzinga.com/government/regulations/25/04/44973571/us-stock-futures-drop-amid-mixed-signals-from-white-house-on-us-china-trade-focus-on-quality-in-a-diversified-manner-says-expert">slipped Thursday morning,</a> giving back gains from a two-day rally, as investor sentiment soured amid conflicting signals on trade policy. Premarket futures for major benchmark indexes traded lower after President Donald Trump suggested a potential deal with China on Tuesday evening, only for Treasury Secretary Scott Bessent to <a href="https://www.benzinga.com/markets/equities/25/04/44970416/scott-bessents-china-de-escalation-scoop-delivered-to-wall-street-early-at-closed-door-event-2-2-trillion-in-gains-later-questions-arise-if-retail-investors-were">dismiss any plans</a> to unilaterally reduce tariffs on Chinese imports the following day. Adding to the uncertainty, China publicly rejected Trump's<a href="https://www.benzinga.com/markets/25/04/44973283/china-denies-trumps-trade-talk-assertion-calls-for-abolition-of-unilateral-tariffs-no-factual-basis"> claims of ongoing trade talks.</a>
The SPDR S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) fell 0.51% to $532.67 and the Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) dropped 0.71% to $451.33 in Thursday's premarket trading, per <a href="http://pro.benzinga.com">Benzinga Pro data.</a>
Read Next: <a href="https://www.benzinga.com/news/25/04/44972378/trump-administration-denies-federal-disaster-aid-to-tornado-stricken-arkansas-pushing-responsibility-to-states">Trump Administration Denies Federal Disaster Aid To Tornado-Stricken Arkansas, Pushing Responsibility To States</a>
Image Via Shutterstock

Politics

Economics

TSLA

Tim Walz Slams Trump Over Tariffs, DOGE Department In Blistering Speech, Calls Him A 'Man Who Wants To Be A King'

Comcast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) reported quarterly earnings of $1.09 per share which beat the analyst consensus estimate of $0.98 by 11.22 percent. This is a 4.81 percent increase over earnings of $1.04 per share from the same period last year. The company reported quarterly sales of $29.89 billion which beat the analyst consensus estimate of $29.76 billion by 0.41 percent. This is a 0.57 percent decrease over sales of $30.06 billion the same period last year.

Comments

DTE Energy Company 2020 Series G 4.375% Junior Subordinated Debentures due 2080

DTE Energy Company 2020 Series G 4.375% Junior Subordinated Debentures due 2080 (DTB) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL